In addition to classic medications, like metformin and insulin, there are several more recent glucose-lowering drugs (GLDs) [9], such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter-2 inhibitors (SGLT2i), that improve glycemic homeostasis with a low/absent risk of hypoglycemia. Here, DPP4 is linked to Hypoglycemia.